SQZ Biotech
134 Coolidge Ave
Second Floor
Watertown
MA
02472
United States
Tel: (603) 490-9117
Website: http://sqzbiotech.com/
84 articles about SQZ Biotech
-
SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Performance at ASGCT 2021
4/27/2021
SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that it will present new data on the company’s scaled cGMP cell therapy manufacturing program at the 2021 American Society for Gene and Cell Therapy Virtual Annual Meeting from May 11-14.
-
SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KRAS Driven Tumors
4/10/2021
SQZ enhanced APCs (eAPCs) demonstrated ability to meaningfully increase CD8 T cell response through incorporation of costimulatory molecules and cytokine signaling
-
SQZ Biotech to Participate in April 2021 Investor Events
4/6/2021
SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that management will be participating in multiple investor conferences in April 2021.
-
SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements
3/18/2021
SQZ Biotech, a cell therapy company developing novel treatments for multiple therapeutic areas, reported full year 2020 financial results and recent business highlights.
-
SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference
3/3/2021
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ™, will present a corporate overview at the upcoming virtual H.C. Wainwright Global Life Sciences Conference. The presentation will be available through the virtual conference portal on Tuesday, March 9, 2021 at 7:00 am EST.
-
SQZ Biotech Announces Pricing of Public Offering of Common Stock
2/12/2021
SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the pricing of its underwritten public offering of 3,000,000 shares of common stock at a public offering price of $20.00 per share.
-
SQZ Biotech Announces Proposed Public Offering of Common Stock
2/9/2021
SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenced an underwritten public offering of 3,000,000 shares of common stock.
-
SQZ Biotechnologies Presents Preclinical Data for their SQZ Tolerizing Antigen Carrier Platform in Antigen-Specific Immune Tolerance (ASIT) Digital Summit Invited Talk
1/27/2021
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel potential treatments for multiple therapeutic areas, announced today that the Immune Tolerance group leader, Shinu John, PhD, will present new preclinical data from the company’s Tolerizing Antigen Carriers (SQZ™ TACs) platform in an invited talk at the Antigen-Specific Immune Tolerance (ASIT) Digital Summit taking place January 26, 2021
-
SQZ Biotech to Present at Evercore ISI Virtual HealthCONx Conference
11/23/2020
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ, will be participating in a fireside chat at the Evercore ISI Virtual HealthCONx Conference
-
SQZ Biotech to Present at November 2020 Virtual Investor Conferences
11/12/2020
SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that Armon Sharei, PhD, chief executive officer of SQZ, and additional management will participate in the following upcoming virtual investor conferences:
-
SQZ Biotech Presents Preclinical Data for SQZ APC and AAC Cellular Vaccine Platforms at SITC 2020, Including First-Time SQZ APC Combination Preclinical Data
11/10/2020
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the presentation of first-time preclinical data for SQZ Antigen Presenting Cells (APCs) in combination with immune-oncology compounds in a poster at the 35th Annual Meeting of The Society for Immun
-
SQZ Biotech Strengthens Board of Directors and Appoints New Chief Business Officer
10/23/2020
Marc Schegerin, MD and Sapna Srivastava, PhD join as new board members and Micah Zajic as Chief Business Officer
-
Biopharma Money on the Move: October 7-14
10/15/2020
Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
SQZ Biotech Appoints Paul Bolno, MD to Board of Directors and Kai Wucherpfennig, MD, PhD to Scientific Advisory Board
7/20/2020
SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appointments of Paul Bolno, MD, to its board of directors, and Kai Wucherpfennig, MD, PhD, to its scientific advisory board. Dr. Bolno is the chief executive officer of Wave Life Sciences and brings over 15 years of experience in both corporate and scientific leadership. Dr. Wu
-
SQZ Biotech to Participate in June 2020 Investor Conferences
5/26/2020
SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that Armon Sharei, PhD, chief executive officer, will be presenting at the following upcoming virtual investor conferences
-
SQZ Biotech Closes $65 Million Series D Financing
5/18/2020
Financing Supports Ongoing Phase 1 Trial of SQZ APC Platform in HPV+ Tumors and Advancement of SQZ AAC Platform towards an Investigational New Drug Application
-
“We are thrilled to have the support of both our new and long-standing investors who believe in SQZ and our potential to create impactful therapies for patients,” said Teri Loxam, SQZ’s chief financial officer.
-
SQZ Biotech to Present at UBS Virtual Global Healthcare Conference
5/11/2020
SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will present a corporate overview at the UBS Virtual Global Healthcare Conference on May 18, 2020 at 10:50am EST.
-
Clinical Catch-Up: January 27-31
2/3/2020
It was another busy week for clinical trial updates. Here’s a look. -
Armon Sharei, chief executive officer of SQZ Biotech, said 2020 is going to be an exciting year for the company as it anticipates having clinical data available from its first trial by the end of this year.